Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Can you use a JAK inhibitor and Mavenclad in a patient with both multiple sclerosis and rheumatoid arthritis?
Related Questions
What is your initial treatment paradigm for someone with both CNS and peripheral neurologic Sjogren’s?
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
How do you approach the "wearing off" phenomenon for patients with multiple sclerosis on B-cell-depleting therapies?
When do you consider pembrolizumab for the treatment of progressive multifocal leukoencephalopathy?
What is the diagnostic approach and management for suspected Hashimoto Encephalitis?
What baseline visual testing, if any, do you recommend at diagnosis for patients with multiple sclerosis who deny visual complaints?
How are you using CSF cytokine panels in autoimmune encephalitis, if at all?
How do you decide on initial and sequential anti-CD20 therapy for patients with multiple sclerosis given the availability of rituximab, ocrelizumab, ublituximab, and ofatumumab?
What are the possible or expected MRI findings or changes in progressive MS?
How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?
